A4cell, backed by BeAble Capital, is thrilled to mark the culmination of an exhilarating year with a significant milestone - the acquisition of a substantial €3 million investment. This momentous investment will serve as the catalyst for revolutionizing the landscape of living single cell analysis.

"We are immensely excited about the possibilities this investment brings, remarked Elena Rivas, CEO of A4CELL. This marks a pivotal moment for A4CELL and underscores our dedication to pushing the boundaries of single cell analysis, particularly in the realm of understanding and combatting complex diseases such as cancer”.

The investment will primarily be channeled towards intensifying research and development efforts, expanding their talented team of researchers and engineers, and accelerating the production of state-of-the-art technologies designed to unlock the secrets hidden within living single cells.

Through an unwavering commitment to innovation and a steadfast vision for the future, A4cell is poised to revolutionize the field of living single cell analysis and transform scientific research.

About A4cell:

A4cell is a leading research and technology company dedicated to advancing the frontier of living single cell analysis. With a focus on pioneering breakthrough technologies, A4CELL aims to unravel the complexities of cellular dynamics to drive critical advancements in the fields of biomedicine and life sciences

Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

CRB Health Tech realiza el primer cierre...

by CRB Inverbío SA SGECR

Con la incorporación de Sanitas y las suscripciones ya firmadas con a...

Photos Stream